Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine
By C. Pauli, B. Hopkins, D. Prandi, Reid Shaw, T. Fedrizzi, A. Sboner, V. Sailer, Michael A. Augello, L. Puca, Rachele Rosati and 19 more. Cancer Discovery, 2017
823 citations recorded by the source corpus.
Precision Medicine is an approach that takes into account the influence of individuals' genes, environment and lifestyle exposures to tailor interventions. Here, we describe the development of a robust precision cancer care platform, which integrates whole exome sequencing (WES) with a living biobank that enables high throughput drug screens on patient-derived tumor organoids. To date, 56 tumor-derived organoid cultures, and 19 patient-derived xenograft (PDX) models have been established from the 769 patients enrolled in an IRB approved clinical trial. Because genomics alone was insufficient to identify therapeutic options for the majority of patients with advanced disease, we used high throughput drug screening effective strategies. Analysis of tumor derived cells from four cases, two uterine malignancies and two colon cancers, identified effective drugs and drug combinations that were subsequently validated using 3D cultures and PDX models. This platform thereby promotes the discovery of novel therapeutic approaches that can be assessed in clinical trials and provides personalized therapeutic options for individual patients where standard clinical options have been exhausted.
Subfields: Biophysics, Cancer Research, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/157b5265d7221c692eb32edbd516701a8808ed39
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Biophysics
In Cancer Research
In Molecular Biology
Citations in the corpus
- Three-Dimensional in Vitro Cell Culture Models in Drug Discovery and Drug Repositioning (2018, background): “…tumoroids derived from patient cancer tissues that contain tumor cells and stroma cells of the tumor microenvironment are poised to provide advanced and more realistic 3D culture platforms for personalized drug evaluation and development (Xu et al., 2014; Stadler et al., 2015; Pauli et al., 2017).”